Sarepta price target lowered to $80 from $105 at Scotiabank

Scotiabank lowered the firm’s price target on Sarepta (SRPT) to $80 from $105 and keeps a Sector Perform rating on the shares. After speaking with four physicians and one nurse practitioner that treat patients with Duchenne Muscular Dystrophy and use Elevidys about the death of a patient who received the treatment, the firm continues to believe Elevidys is a good drug, the analyst tells investors. However, Scotiabank intends to remain on the sidelines for now and would like to see if the update impacts uptake.